EARLY LUNG CANCER - The use of molecular biomarkers in early lung cancer detection (EARLY LUNG CANCER) (LIFE QUALITY) (2002-11-01 - 2006-10-31) (»add to infobox)

Barry HEWITSON, Quentin COEY, Hedwig DARLEY, Philippe BOULANGE, Otmar D. WIESTLER, Francisco ERRASTI, Christian BRECHOT, Andrea MATTIUSSI, Dieter BOPP, Jan GORSKI, N. N. THORAXKLINIK - HEIDELBERG GGMBH, Grace DEMPSEY, Robert SMAILES, Peter GILLESPIE, Chris MEIJER

UNIVERSITY OF LIVERPOOL (UK840 - Merseyside) (Great Britain), BELFAST CITY HOSPITAL TRUST (UKB00 - Northern Ireland) (Great Britain), CANISIUS WILHELMINA ZIEKENHUIS (NL223 - Arnhem/Nijmegen) (Netherlands), CENTRE HOSPITALIER REGIONAL UNIVERS ITAIRE NANCY (FR411 - Meurthe-et-Moselle) (France), DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG (DE125 - Heidelberg, Stadtkreis) (Germany), FUNDACION PARA LA INVESTIGACION MED ICA APLICADA FIMA (ES220 - Navarra) (Spain), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR714 - Isère) (France), ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI (ITC45 - Milano) (Italy), KLINIK LOEWENSTEIN (DE118 - Heilbronn, Landkreis) (Germany), MEDICAL UNIVERSITY OF BIALYSTOK (PL0A1 - Podlaskie Bialostocko-Suwalski) (Poland), THORAXKLINIK - HEIDELBERG GGMBH (DE125 - Heidelberg, Stadtkreis) (Germany), TRINITY COLLEGE DUBLIN (IE002 - Dublin) (Ireland), UNIVERSITY OF EDINBURGH (UKA14 - Lothian) (Great Britain), UNIVERSITY OF LEICESTER (UK321 - Leicestershire) (Great Britain), VRIJE UNIVERSITEIT MEDISCH CENTRUM (NL326 - Groot-Amsterdam) (Netherlands)

The overall goal of the project involving 12 Partners is to determine if specific genetic changes in lung carcinogenesis are detectable in the respiratory epithelium of individuals who have an increased risk of developing lung cancer. Partners are enrolling 1200 individuals with a very high risk of developing lung cancer i.e. Second Primary Lung Cancers (SPLC) in 12 clinical centres in Europe. The recruited individuals will be followed-up over 3 years, 1-3% per year will develop SPLC (-100 SPLC). Specimens obtained will be 'banked' and assessed for a range of molecular/pathological markers considered to be involved in carcinogenesis. We have tackled the question of early detection on a molecular pathway approach and plan to examine; oncogenic pathways and cell cycle regulation, genetic instability, angiogenic and growth factors, signal pathways, post-transcriptional regulation genomic expression profiling and genotyping.

PERSONS (15/15)

RELATED NAVIGATION AREA(S) (2/2)